Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000669414 | SCV000794163 | likely pathogenic | Smith-Lemli-Opitz syndrome | 2017-09-19 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000669414 | SCV004466857 | pathogenic | Smith-Lemli-Opitz syndrome | 2023-05-16 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the DHCR7 protein in which other variant(s) (p.Val466Met) have been determined to be pathogenic (PMID: 21990131, 22391996, 23042628; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 553880). This variant has not been reported in the literature in individuals affected with DHCR7-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Pro335Argfs*78) in the DHCR7 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 141 amino acid(s) of the DHCR7 protein. |